The correlation of POLE mutation with PD1/PD-L1 immunotherapy in colorectal cancer and endometrial cancer [22–24] leads us towards further research to explore whether there is a treatment option for immunotherapy in POLE-mutated IBC. Here, CD274 is linked to inflammatory breast carcinoma.